candesartan cilexetil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
angiotensin II receptor antagonists, antihypertensive (non-peptidic)	475	145040-37-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: candesartan cilexetil TCV-116 TCV 116	a nonpeptide angiotensin II receptor antagonist Molecular weight: 610.67 Formula: C33H34N6O6 CLOGP: 7.08 LIPINSKI: 3 HAC: 12 HDO: 1 TPSA: 143.34 ALOGS: -5.48 ROTB: 13 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
8	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.05 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.61 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
June 4, 1998	FDA	ASTRAZENECA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	385.57	10.18	888	57803	234967	46392404
Hyponatraemia	354.36	10.18	530	58161	100802	46526569
Hyperkalaemia	163.96	10.18	256	58435	50453	46576918
Drug ineffective	148.35	10.18	404	58287	677434	45949937
General physical health deterioration	140.48	10.18	390	58301	115379	46511992
Oligohydramnios	123.30	10.18	80	58611	5385	46621986
Completed suicide	121.59	10.18	19	58672	145901	46481470
Product dose omission issue	119.65	10.18	32	58659	168488	46458883
Death	98.79	10.18	169	58522	335379	46291992
Drug interaction	98.05	10.18	509	58182	202585	46424786
Drug hypersensitivity	97.14	10.18	98	58593	243727	46383644
Bradycardia	95.28	10.18	238	58453	66060	46561311
Angina pectoris	93.30	10.18	140	58551	26635	46600736
Lactic acidosis	90.43	10.18	157	58534	33752	46593619
Cardiac failure	86.89	10.18	259	58432	79689	46547682
Pain	81.24	10.18	317	58374	476631	46150740
Syncope	80.51	10.18	302	58389	104501	46522870
Orthostatic hypotension	78.98	10.18	124	58567	24534	46602837
Blood pressure increased	75.15	10.18	337	58354	126329	46501042
Hypotension	75.14	10.18	525	58166	232064	46395307
Inappropriate antidiuretic hormone secretion	73.99	10.18	90	58601	14012	46613359
Dizziness	69.11	10.18	692	57999	339722	46287649
Hypertensive crisis	68.38	10.18	85	58606	13530	46613841
Injection site pain	67.70	10.18	25	58666	107127	46520244
Blood creatinine increased	66.17	10.18	229	58462	76174	46551197
Rheumatoid arthritis	60.99	10.18	132	58559	240083	46387288
Renal impairment	60.18	10.18	218	58473	74154	46553217
Fall	55.60	10.18	645	58046	328452	46298919
Synovitis	55.53	10.18	6	58685	61069	46566302
Arterial occlusive disease	55.49	10.18	47	58644	4757	46622614
Hypertension	53.03	10.18	425	58266	195931	46431440
Maternal exposure during pregnancy	52.41	10.18	32	58659	102517	46524854
Hypoglycaemia	49.77	10.18	166	58525	54183	46573188
Labile hypertension	49.53	10.18	20	58671	488	46626883
Disorientation	49.34	10.18	129	58562	36789	46590582
Haematochezia	48.07	10.18	129	58562	37364	46590007
Circulatory collapse	43.77	10.18	89	58602	21535	46605836
Sputum discoloured	43.35	10.18	66	58625	12712	46614659
Confusional state	42.56	10.18	345	58346	159547	46467824
Alopecia	42.23	10.18	88	58603	162326	46465045
Vertigo	41.61	10.18	152	58539	51896	46575475
Rubber sensitivity	41.16	10.18	26	58665	1670	46625701
Product use issue	40.00	10.18	36	58655	94608	46532763
Injection site erythema	39.76	10.18	22	58669	74405	46552966
Cough	39.13	10.18	452	58239	229797	46397574
Basilar artery occlusion	38.93	10.18	12	58679	127	46627244
Atrial fibrillation	37.67	10.18	241	58450	103349	46524022
Gamma-glutamyltransferase increased	37.50	10.18	106	58585	31634	46595737
Rhabdomyolysis	37.47	10.18	127	58564	41782	46585589
Swelling	37.19	10.18	62	58629	124449	46502922
Cerebral infarction	36.87	10.18	87	58604	23279	46604092
Androgenetic alopecia	36.14	10.18	12	58679	164	46627207
Arthropathy	36.06	10.18	32	58659	84668	46542703
Pemphigoid	36.01	10.18	40	58651	5651	46621720
Altered state of consciousness	34.76	10.18	85	58606	23263	46604108
Diffuse alopecia	34.68	10.18	16	58675	544	46626827
Anaemia	34.07	10.18	480	58211	255299	46372072
Psychomotor retardation	34.04	10.18	30	58661	3203	46624168
Lung opacity	33.45	10.18	20	58671	1164	46626207
Gangrene	33.21	10.18	35	58656	4660	46622711
Hand deformity	32.46	10.18	3	58688	34571	46592800
Vasoplegia syndrome	32.30	10.18	19	58672	1073	46626298
Renal failure	31.78	10.18	248	58443	113346	46514025
Non-cardiogenic pulmonary oedema	31.49	10.18	15	58676	549	46626822
Occupational asthma	30.79	10.18	10	58681	127	46627244
Anuria	30.56	10.18	53	58638	11378	46615993
Glossodynia	30.38	10.18	9	58682	44364	46583007
Forced expiratory volume decreased	29.12	10.18	34	58657	5070	46622301
Product prescribing error	28.80	10.18	72	58619	19975	46607396
Off label use	28.05	10.18	324	58367	379517	46247854
Drug intolerance	28.04	10.18	93	58598	146956	46480415
Toxicity to various agents	28.03	10.18	154	58537	211612	46415759
Lichen planus	27.71	10.18	21	58670	1812	46625559
Therapeutic product effect incomplete	27.16	10.18	35	58656	78118	46549253
Haematoma muscle	27.05	10.18	14	58677	614	46626757
Sinusitis	26.91	10.18	79	58612	129689	46497682
Osteochondrosis	26.41	10.18	16	58675	954	46626417
Hospitalisation	25.73	10.18	25	58666	63360	46564011
Fibromyalgia	25.70	10.18	7	58684	36456	46590915
Oesophageal dilatation	25.16	10.18	11	58680	329	46627042
Gastrointestinal tract adenoma	25.16	10.18	11	58680	329	46627042
Blood hyposmosis	25.08	10.18	6	58685	21	46627350
Injection site reaction	24.34	10.18	15	58676	47834	46579537
Peripheral swelling	24.33	10.18	109	58582	157962	46469409
Carcinoid tumour of the caecum	24.26	10.18	6	58685	25	46627346
Barotrauma	23.86	10.18	9	58682	182	46627189
Pulmonary hypoplasia	23.38	10.18	10	58681	283	46627088
No adverse event	23.33	10.18	7	58684	34224	46593147
Disease progression	23.26	10.18	50	58641	91250	46536121
Multiple sclerosis relapse	23.16	10.18	12	58679	42113	46585258
Haematoma	22.92	10.18	90	58601	31782	46595589
Internal haemorrhage	22.67	10.18	28	58663	4427	46622944
Mental status changes	22.23	10.18	10	58681	38078	46589293
Abdominal discomfort	22.22	10.18	106	58585	151059	46476312
Treatment failure	22.08	10.18	53	58638	93034	46534337
Infection	21.85	10.18	90	58601	133502	46493869
Shock haemorrhagic	21.78	10.18	39	58652	8585	46618786
Abortion spontaneous	21.76	10.18	14	58677	43632	46583739
Arrhythmia	21.61	10.18	94	58597	34747	46592624
Tinnitus	21.43	10.18	80	58611	27593	46599778
Product quality issue	21.38	10.18	9	58682	35639	46591732
Purpura senile	21.32	10.18	12	58679	623	46626748
Cerebellar syndrome	21.32	10.18	24	58667	3441	46623930
Cornea verticillata	21.07	10.18	6	58685	47	46627324
Renal impairment neonatal	21.01	10.18	5	58686	17	46627354
Metastases to fallopian tube	20.96	10.18	6	58685	48	46627323
Prerenal failure	20.71	10.18	16	58675	1421	46625950
Myalgia	20.58	10.18	241	58450	122847	46504524
Interstitial lung disease	20.52	10.18	127	58564	53822	46573549
Intravascular haemolysis	20.46	10.18	9	58682	273	46627098
Gastrointestinal disorder	20.37	10.18	27	58664	59549	46567822
Palpitations	20.37	10.18	196	58495	95063	46532308
Disturbance in attention	20.23	10.18	86	58605	31474	46595897
Sinus arrest	20.12	10.18	17	58674	1714	46625657
Thyroid stimulating immunoglobulin increased	20.07	10.18	7	58684	112	46627259
Injection site swelling	20.02	10.18	13	58678	40314	46587057
Atrioventricular block complete	19.91	10.18	35	58656	7592	46619779
Dyspnoea	19.86	10.18	814	57877	514734	46112637
Melaena	19.63	10.18	78	58613	27694	46599677
Occult blood	19.61	10.18	13	58678	907	46626464
Mental status changes postoperative	19.37	10.18	8	58683	207	46627164
Renal aplasia	19.16	10.18	8	58683	213	46627158
Oedema peripheral	18.98	10.18	294	58397	159412	46467959
Histamine intolerance	18.85	10.18	5	58686	29	46627342
Confusion postoperative	18.82	10.18	8	58683	223	46627148
Intentional overdose	18.77	10.18	33	58658	64911	46562460
Neutropenia	18.47	10.18	105	58586	143099	46484272
Dehydration	18.32	10.18	292	58399	159248	46468123
Urinary retention	18.26	10.18	73	58618	25988	46601383
Joint swelling	18.21	10.18	128	58563	165945	46461426
Injection site pruritus	18.16	10.18	14	58677	39729	46587642
Blood creatine phosphokinase increased	18.12	10.18	76	58615	27648	46599723
Painful respiration	18.10	10.18	19	58672	2518	46624853
Putamen haemorrhage	17.97	10.18	7	58684	155	46627216
Hypouricaemia	17.84	10.18	7	58684	158	46627213
Psoas abscess	17.64	10.18	9	58682	383	46626988
Blood uric acid increased	17.62	10.18	24	58667	4177	46623194
Glomerulonephritis chronic	17.60	10.18	7	58684	164	46627207
Vertigo positional	17.53	10.18	19	58672	2611	46624760
Acute myocardial infarction	17.46	10.18	83	58608	31841	46595530
Thirst	17.46	10.18	41	58650	10935	46616436
Total lung capacity decreased	17.42	10.18	13	58678	1096	46626275
Vital capacity decreased	17.09	10.18	10	58681	559	46626812
Tubulointerstitial nephritis	17.09	10.18	49	58642	14739	46612632
Heart rate	17.04	10.18	5	58686	44	46627327
Multiple sclerosis	17.02	10.18	5	58686	24786	46602585
Rash	16.98	10.18	331	58360	356181	46271190
Vestibular migraine	16.92	10.18	6	58685	101	46627270
Hypokalaemia	16.83	10.18	177	58514	87847	46539524
Blood pressure inadequately controlled	16.73	10.18	24	58667	4382	46622989
Hypoosmolar state	16.67	10.18	7	58684	189	46627182
Female sterilisation	16.66	10.18	10	58681	586	46626785
Productive cough	16.61	10.18	115	58576	50600	46576771
Wrong strength	16.57	10.18	5	58686	49	46627322
Transaminases increased	16.53	10.18	74	58617	27687	46599684
Intentional product misuse	16.48	10.18	21	58670	47107	46580264
Dermatosis	16.42	10.18	8	58683	308	46627063
Exposure during pregnancy	16.41	10.18	75	58616	108137	46519234
Hepatic function abnormal	16.36	10.18	86	58605	34335	46593036
Ventricular extrasystoles	16.17	10.18	40	58651	11023	46616348
Iron deficiency anaemia	16.14	10.18	53	58638	17153	46610218
Diabetic ketoacidosis	16.11	10.18	55	58636	18155	46609216
Prothrombin time shortened	15.93	10.18	15	58676	1744	46625627
Potentiating drug interaction	15.83	10.18	22	58669	3901	46623470
Sepsis	15.82	10.18	103	58588	135911	46491460
Tarsal tunnel syndrome	15.79	10.18	10	58681	645	46626726
Spider naevus	15.78	10.18	6	58685	124	46627247
International normalised ratio increased	15.77	10.18	107	58584	46776	46580595
Injection site bruising	15.72	10.18	13	58678	35623	46591748
Chromaturia	15.67	10.18	48	58643	14971	46612400
Chest wall mass	15.65	10.18	5	58686	60	46627311
Neuropathy peripheral	15.64	10.18	60	58631	90833	46536538
Serum serotonin increased	15.61	10.18	6	58685	128	46627243
Mobility decreased	15.59	10.18	33	58658	60561	46566810
Hypomagnesaemia	15.39	10.18	62	58629	22148	46605223
Plasma cell myeloma	15.36	10.18	20	58671	44458	46582913
C-reactive protein increased	15.33	10.18	126	58565	58464	46568907
Sensitivity to weather change	15.30	10.18	26	58665	5490	46621881
Adverse drug reaction	15.27	10.18	20	58671	44342	46583029
Vestibular disorder	15.03	10.18	13	58678	1353	46626018
Cor pulmonale acute	15.02	10.18	8	58683	372	46626999
Cerebral haemorrhage	14.97	10.18	73	58618	28298	46599073
Walking disability	14.94	10.18	13	58678	1365	46626006
Contraindicated product administered	14.93	10.18	51	58640	79896	46547475
Systemic lupus erythematosus	14.76	10.18	38	58653	65142	46562229
Pneumobilia	14.57	10.18	6	58685	154	46627217
Lip infection	14.34	10.18	5	58686	80	46627291
Full blood count decreased	14.33	10.18	5	58686	22206	46605165
Nasal congestion	14.31	10.18	24	58667	48089	46579282
Dyspnoea at rest	14.30	10.18	20	58671	3568	46623803
Bradyarrhythmia	14.27	10.18	15	58676	1991	46625380
Metastases to bladder	14.19	10.18	6	58685	165	46627206
Hyperuricaemia	14.11	10.18	23	58668	4694	46622677
Retroperitoneal haematoma	14.09	10.18	17	58674	2623	46624748
Gastroenteritis	14.00	10.18	64	58627	24155	46603216
Binocular eye movement disorder	13.97	10.18	4	58687	32	46627339
Cerebral haematoma	13.89	10.18	19	58672	3320	46624051
Cardiorenal syndrome	13.80	10.18	9	58682	611	46626760
Unevaluable event	13.77	10.18	23	58668	46152	46581219
Blood sodium decreased	13.76	10.18	59	58632	21667	46605704
Glomerular filtration rate decreased	13.76	10.18	39	58652	11655	46615716
Therapy non-responder	13.71	10.18	19	58672	41133	46586238
Decreased appetite	13.51	10.18	329	58362	193507	46433864
Staphylococcal infection	13.51	10.18	15	58676	35756	46591615
Aortic dissection	13.33	10.18	13	58678	1579	46625792
Aphasia	13.32	10.18	71	58620	28496	46598875
Hypochloraemia	13.31	10.18	14	58677	1859	46625512
Glossitis	13.28	10.18	17	58674	2786	46624585
Hallucinations, mixed	13.22	10.18	20	58671	3829	46623542
Cardiac murmur functional	13.18	10.18	4	58687	40	46627331
Accidental exposure to product	13.17	10.18	5	58686	21076	46606295
Miosis	13.00	10.18	27	58664	6630	46620741
Crystal arthropathy	12.95	10.18	6	58685	206	46627165
Retroperitoneal fibrosis	12.94	10.18	7	58684	336	46627035
Subarachnoid haemorrhage	12.93	10.18	37	58654	11116	46616255
Treatment noncompliance	12.93	10.18	11	58680	29720	46597651
Drug metabolising enzyme decreased	12.89	10.18	3	58688	9	46627362
Pericarditis	12.88	10.18	7	58684	23920	46603451
Eczema nummular	12.77	10.18	6	58685	213	46627158
Device capturing issue	12.76	10.18	4	58687	45	46627326
Polyuria	12.69	10.18	28	58663	7167	46620204
Clostridium difficile infection	12.58	10.18	8	58683	25095	46602276
Blood urea increased	12.50	10.18	64	58627	25288	46602083
Febrile neutropenia	12.40	10.18	69	58622	94558	46532813
Tenderness	12.36	10.18	3	58688	16878	46610493
Gastrointestinal haemorrhage	12.27	10.18	150	58541	77223	46550148
Endometrial cancer stage I	12.27	10.18	6	58685	233	46627138
Arthralgia	12.23	10.18	357	58334	364246	46263125
Wrong technique in product usage process	12.11	10.18	32	58659	54390	46572981
Malaise	12.03	10.18	520	58171	330712	46296659
Seizure	11.99	10.18	98	58593	122956	46504415
Drug monitoring procedure not performed	11.92	10.18	7	58684	394	46626977
Anaemia folate deficiency	11.90	10.18	6	58685	249	46627122
Pharyngeal enanthema	11.89	10.18	4	58687	57	46627314
Electrolyte imbalance	11.87	10.18	48	58643	17178	46610193
Pregnancy	11.85	10.18	10	58681	27127	46600244
Ischaemic stroke	11.84	10.18	47	58644	16675	46610696
Drug therapeutic incompatibility	11.83	10.18	4	58687	58	46627313
Gastroenteritis viral	11.82	10.18	4	58687	18115	46609256
Thrombosis	11.71	10.18	34	58657	56035	46571336
Loss of personal independence in daily activities	11.71	10.18	35	58656	57148	46570223
Hepatic enzyme increased	11.63	10.18	58	58633	81729	46545642
Pain in jaw	11.54	10.18	19	58672	38353	46589018
Foetal malformation	11.48	10.18	5	58686	148	46627223
Brain stem stroke	11.45	10.18	6	58685	270	46627101
Labelled drug-drug interaction medication error	11.43	10.18	31	58660	9030	46618341
Therapy cessation	11.40	10.18	10	58681	26619	46600752
Intraventricular haemorrhage	11.39	10.18	13	58678	1892	46625479
Retinopathy of prematurity	11.37	10.18	6	58685	274	46627097
Transient ischaemic attack	11.34	10.18	79	58612	34824	46592547
Proteinuria	11.30	10.18	46	58645	16507	46610864
Anti-thyroid antibody positive	11.25	10.18	7	58684	438	46626933
Iron deficiency	11.24	10.18	23	58668	5590	46621781
Base excess decreased	11.19	10.18	4	58687	69	46627302
Product impurity	11.19	10.18	4	58687	69	46627302
Lordosis	11.19	10.18	6	58685	283	46627088
Aplasia pure red cell	11.16	10.18	20	58671	4405	46622966
Carcinoid tumour	11.09	10.18	6	58685	288	46627083
Blood pressure systolic increased	11.09	10.18	68	58623	28719	46598652
Delayed fontanelle closure	11.09	10.18	3	58688	19	46627352
Blood sodium abnormal	11.05	10.18	8	58683	644	46626727
Polyneuropathy	11.04	10.18	36	58655	11608	46615763
Visual acuity reduced transiently	11.03	10.18	5	58686	163	46627208
Spinal osteoarthritis	11.03	10.18	41	58650	14110	46613261
Hypoaesthesia	10.98	10.18	96	58595	118773	46508598
Resorption bone increased	10.96	10.18	10	58681	1117	46626254
Congestive cardiomyopathy	10.95	10.18	23	58668	5690	46621681
Stasis dermatitis	10.95	10.18	8	58683	653	46626718
Gastritis bacterial	10.93	10.18	4	58687	74	46627297
Device dislocation	10.86	10.18	7	58684	21795	46605576
Complication associated with device	10.81	10.18	3	58688	15438	46611933
Procalcitonin increased	10.81	10.18	8	58683	666	46626705
Dyscalculia	10.71	10.18	3	58688	22	46627349
Hepatitis cholestatic	10.68	10.18	25	58666	6652	46620719
Infusion related reaction	10.60	10.18	79	58612	101129	46526242
Incarcerated incisional hernia	10.59	10.18	3	58688	23	46627348
Chemotherapeutic drug level increased	10.57	10.18	5	58686	180	46627191
Laboratory test abnormal	10.50	10.18	8	58683	22839	46604532
Blood pressure decreased	10.49	10.18	114	58577	57045	46570326
Drug dependence	10.45	10.18	6	58685	19895	46607476
Vitamin B12 decreased	10.37	10.18	15	58676	2760	46624611
Skin texture abnormal	10.36	10.18	6	58685	329	46627042
Necrotising myositis	10.34	10.18	6	58685	330	46627041
Stress urinary incontinence	10.29	10.18	13	58678	2103	46625268
Agranulocytosis	10.25	10.18	55	58636	22130	46605241
White blood cell count decreased	10.21	10.18	91	58600	112140	46515231

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperkalaemia	150.84	10.50	320	45449	65690	29841019
General physical health deterioration	146.36	10.50	408	45361	99536	29807173
Acute kidney injury	135.24	10.50	795	44974	273047	29633662
Death	133.69	10.50	213	45556	357070	29549639
Completed suicide	126.87	10.50	6	45763	99486	29807223
Product monitoring error	126.54	10.50	59	45710	1682	29905027
Haematochezia	86.44	10.50	173	45596	34049	29872660
Product dose omission issue	75.62	10.50	23	45746	91608	29815101
Drug abuse	72.60	10.50	18	45751	82054	29824655
Toxicity to various agents	72.47	10.50	99	45670	177084	29729625
Bradycardia	62.43	10.50	231	45538	65295	29841414
Hypertension	58.06	10.50	350	45419	121004	29785705
Neutropenia	50.34	10.50	74	45695	128466	29778243
Dizziness	49.22	10.50	484	45285	194425	29712284
Pulmonary hypoplasia	48.93	10.50	20	45749	411	29906298
Cardiac failure	48.08	10.50	253	45516	83165	29823544
Product prescribing error	46.38	10.50	88	45681	16645	29890064
Angina pectoris	44.56	10.50	122	45647	29396	29877313
Renal impairment	44.25	10.50	249	45520	83935	29822774
Interstitial lung disease	43.62	10.50	195	45574	60002	29846707
Pemphigoid	37.97	10.50	52	45717	7476	29899233
Plasma cell myeloma	36.51	10.50	18	45751	53444	29853265
Electrolyte imbalance	36.32	10.50	64	45705	11436	29895273
Vitamin D deficiency	36.09	10.50	42	45727	5128	29901581
Presyncope	34.49	10.50	76	45693	15980	29890729
Anencephaly	33.87	10.50	11	45758	113	29906596
Nipple inflammation	33.80	10.50	10	45759	73	29906636
Lymphocyte count abnormal	33.61	10.50	17	45752	581	29906128
Renal artery thrombosis	33.25	10.50	14	45755	311	29906398
Drug ineffective	32.60	10.50	348	45421	340039	29566670
Cerebral infarction	31.22	10.50	100	45669	26273	29880436
Drug interaction	30.28	10.50	450	45319	199118	29707591
Patient dissatisfaction with treatment	30.27	10.50	9	45760	67	29906642
Disease progression	30.26	10.50	47	45722	79827	29826882
Myalgia	29.81	10.50	210	45559	76457	29830252
C-reactive protein decreased	29.06	10.50	22	45747	1556	29905153
Blood pressure increased	28.54	10.50	198	45571	71730	29834979
Seizure	28.54	10.50	68	45701	98407	29808302
Agitation	27.78	10.50	25	45744	54048	29852661
Labelled drug-drug interaction medication error	27.46	10.50	54	45715	10484	29896225
Hospitalisation	27.25	10.50	17	45752	44302	29862407
Oedema peripheral	27.22	10.50	264	45505	105568	29801141
Neuropathy peripheral	27.15	10.50	41	45728	70434	29836275
Arrhythmia	26.74	10.50	111	45658	33058	29873651
Blood creatinine increased	26.55	10.50	234	45535	91141	29815568
Blood cholesterol	26.37	10.50	9	45760	109	29906600
Hyperuricaemia	25.78	10.50	43	45726	7351	29899358
Cardiac arrest	25.43	10.50	66	45703	92784	29813925
Off label use	25.41	10.50	251	45518	249039	29657670
Nipple disorder	25.04	10.50	10	45759	193	29906516
Peripheral arterial occlusive disease	25.02	10.50	35	45734	5133	29901576
Respiratory arrest	24.74	10.50	7	45762	29251	29877458
Joint contracture	24.29	10.50	21	45748	1794	29904915
Lactic acidosis	24.03	10.50	103	45666	31110	29875599
Colitis	23.96	10.50	102	45667	30718	29875991
Hypertensive crisis	23.21	10.50	44	45725	8313	29898396
Intentional product misuse	23.17	10.50	12	45757	34655	29872054
Dyspnoea	22.50	10.50	667	45102	332628	29574081
Pain	22.44	10.50	163	45606	172478	29734231
Intestinal haemorrhage	22.33	10.50	26	45743	3175	29903534
Hemiataxia	22.21	10.50	6	45763	30	29906679
Hyponatraemia	22.12	10.50	177	45592	67025	29839684
Mucosal haemorrhage	21.84	10.50	18	45751	1440	29905269
Mental status changes	21.74	10.50	15	45754	37064	29869645
Sepsis	21.64	10.50	133	45636	146262	29760447
Acute cutaneous lupus erythematosus	21.54	10.50	7	45762	72	29906637
Diabetes mellitus inadequate control	21.54	10.50	55	45714	12707	29894002
Pneumonia	21.39	10.50	371	45398	333935	29572774
Blood glucose fluctuation	21.10	10.50	27	45742	3634	29903075
Gastrointestinal ischaemia	21.08	10.50	9	45760	207	29906502
Food aversion	21.07	10.50	10	45759	297	29906412
Febrile neutropenia	20.83	10.50	88	45681	106605	29800104
Haematoma	20.77	10.50	82	45687	23871	29882838
Hypoxia	20.26	10.50	26	45743	47828	29858881
Urinary hesitation	20.18	10.50	21	45748	2263	29904446
Nervous system neoplasm	20.05	10.50	8	45761	154	29906555
Oral lichen planus	19.37	10.50	8	45761	169	29906540
Vasculitic rash	19.28	10.50	14	45755	929	29905780
Duodenal ulcer	19.19	10.50	45	45724	9856	29896853
Eczema eyelids	19.03	10.50	5	45764	22	29906687
Gamma-glutamyltransferase increased	18.98	10.50	92	45677	29258	29877451
Mixed liver injury	18.83	10.50	19	45750	1974	29904735
Basilar artery thrombosis	18.35	10.50	7	45762	119	29906590
Jaundice	18.32	10.50	98	45671	32388	29874321
Pallor	18.20	10.50	72	45697	20977	29885732
Tonsillar ulcer	18.16	10.50	8	45761	199	29906510
Anxiety disorder due to a general medical condition	17.91	10.50	4	45765	7	29906702
Atrioventricular block second degree	17.85	10.50	23	45746	3117	29903592
Congenital renal disorder	17.63	10.50	6	45763	72	29906637
Macular ischaemia	17.20	10.50	6	45763	78	29906631
Unevaluable event	17.17	10.50	14	45755	31771	29874938
Blood creatine phosphokinase increased	16.97	10.50	120	45649	43728	29862981
Hepatic function abnormal	16.94	10.50	116	45653	41829	29864880
Blood pressure fluctuation	16.89	10.50	62	45707	17441	29889268
Cerebral haematoma	16.75	10.50	27	45742	4487	29902222
Paresis cranial nerve	16.66	10.50	6	45763	86	29906623
Congenital vas deferens absence	16.61	10.50	5	45764	39	29906670
Congenital muscle absence	16.61	10.50	5	45764	39	29906670
Hallucination	16.61	10.50	31	45738	49028	29857681
Skull malformation	16.54	10.50	9	45760	358	29906351
Choroidal detachment	16.52	10.50	9	45760	359	29906350
Supine hypertension	16.51	10.50	8	45761	249	29906460
Blood pressure inadequately controlled	16.49	10.50	20	45749	2550	29904159
Device lead damage	16.46	10.50	3	45766	0	29906709
Incarcerated inguinal hernia	16.41	10.50	6	45763	90	29906619
Xanthopsia	16.36	10.50	7	45762	162	29906547
Syncope	16.35	10.50	200	45569	84703	29822006
Muscle rupture	16.10	10.50	18	45751	2103	29904606
Fracture	15.92	10.50	31	45738	5975	29900734
Retinal artery occlusion	15.81	10.50	16	45753	1668	29905041
Oliguria	15.74	10.50	35	45734	7404	29899305
Hepatic ischaemia	15.71	10.50	9	45760	396	29906313
Sedation	15.66	10.50	3	45766	16370	29890339
Treatment failure	15.57	10.50	18	45751	34661	29872048
Pancreatitis acute	15.51	10.50	79	45690	25616	29881093
Alopecia universalis	15.51	10.50	5	45764	50	29906659
Shock hypoglycaemic	15.36	10.50	6	45763	109	29906600
Hypotension	15.33	10.50	408	45361	200157	29706552
Gastrointestinal disorder	15.27	10.50	84	45685	28053	29878656
Oligohydramnios	15.09	10.50	8	45761	302	29906407
Aortic valve incompetence	15.03	10.50	27	45742	4896	29901813
Abdominal pain lower	14.94	10.50	38	45731	8760	29897949
Prolonged expiration	14.93	10.50	7	45762	202	29906507
Primary hyperaldosteronism	14.85	10.50	5	45764	58	29906651
Drug dependence	14.79	10.50	7	45762	21288	29885421
Full blood count decreased	14.78	10.50	3	45766	15714	29890995
Rhabdomyolysis	14.60	10.50	155	45614	63425	29843284
Renin increased	14.55	10.50	5	45764	62	29906647
Papillary renal cell carcinoma	14.52	10.50	6	45763	127	29906582
Coronavirus infection	14.48	10.50	22	45747	3476	29903233
Desmoplastic melanoma	14.38	10.50	3	45766	3	29906706
Eczema	14.31	10.50	49	45720	13320	29893389
Therapeutic product effect decreased	14.27	10.50	14	45755	29062	29877647
Sinusitis	14.24	10.50	18	45751	33327	29873382
White blood cell count decreased	14.16	10.50	73	45696	83874	29822835
Melaena	13.87	10.50	91	45678	32346	29874363
COVID-19	13.83	10.50	5	45764	17873	29888836
Multiple drug therapy	13.82	10.50	7	45762	240	29906469
Excessive eye blinking	13.71	10.50	7	45762	244	29906465
Cardiovascular insufficiency	13.66	10.50	14	45755	1482	29905227
Vasoplegia syndrome	13.66	10.50	13	45756	1258	29905451
Basal ganglia haemorrhage	13.65	10.50	11	45758	852	29905857
Total cholesterol/HDL ratio increased	13.59	10.50	6	45763	150	29906559
Therapy non-responder	13.54	10.50	15	45754	29438	29877271
Hypozincaemia	13.52	10.50	3	45766	5	29906704
Hepatitis acute	13.52	10.50	32	45737	7051	29899658
Condition aggravated	13.42	10.50	290	45479	137576	29769133
Drug resistance	13.41	10.50	7	45762	20126	29886583
Brain stem infarction	13.36	10.50	13	45756	1293	29905416
Vertebral artery stenosis	13.31	10.50	6	45763	158	29906551
Product quality issue	13.31	10.50	6	45763	18768	29887941
Orthostatic hypotension	13.29	10.50	72	45697	23907	29882802
No adverse event	13.26	10.50	5	45764	17414	29889295
Renal ischaemia	13.26	10.50	9	45760	536	29906173
Prothrombin time shortened	13.21	10.50	14	45755	1541	29905168
Rhinalgia	13.20	10.50	8	45761	391	29906318
Periorbital discomfort	13.20	10.50	4	45765	32	29906677
Vascular stent thrombosis	13.07	10.50	17	45752	2326	29904383
Palmar-plantar erythrodysaesthesia syndrome	12.96	10.50	51	45718	14819	29891890
Cranial sutures widening	12.95	10.50	5	45764	88	29906621
Mechanical urticaria	12.84	10.50	5	45764	90	29906619
Hepatocellular carcinoma	12.82	10.50	38	45731	9572	29897137
Neurologic neglect syndrome	12.71	10.50	6	45763	176	29906533
Thrombocytopenia	12.69	10.50	141	45628	136903	29769806
Adrenal insufficiency	12.68	10.50	40	45729	10423	29896286
Unresponsive to stimuli	12.65	10.50	13	45756	26406	29880303
Hypoglycaemia	12.51	10.50	126	45643	50855	29855854
Product use in unapproved indication	12.47	10.50	64	45705	73629	29833080
Myopia	12.43	10.50	9	45760	594	29906115
Aortic valve disease mixed	12.36	10.50	5	45764	100	29906609
Lip ulceration	12.32	10.50	10	45759	783	29905926
Mesenteric artery thrombosis	12.24	10.50	8	45761	447	29906262
Coronary artery stenosis	12.23	10.50	36	45733	9034	29897675
Hypochromic anaemia	12.20	10.50	10	45759	794	29905915
Subileus	12.19	10.50	19	45750	3068	29903641
Glycosylated haemoglobin increased	12.16	10.50	37	45732	9454	29897255
Renal failure	12.14	10.50	270	45499	128696	29778013
Pterygium	11.96	10.50	5	45764	109	29906600
Anti-erythropoietin antibody negative	11.95	10.50	6	45763	202	29906507
Neuroleptic malignant syndrome	11.88	10.50	5	45764	16290	29890419
Stomal hernia	11.88	10.50	5	45764	111	29906598
Antinuclear antibody increased	11.68	10.50	6	45763	212	29906497
Neonatal hypotension	11.55	10.50	5	45764	119	29906590
Wrong dose	11.46	10.50	7	45762	347	29906362
Neurotoxicity	11.43	10.50	3	45766	13179	29893530
Breast pain	11.37	10.50	12	45757	1315	29905394
Generalised tonic-clonic seizure	11.34	10.50	8	45761	19543	29887166
Gastric dilatation	11.28	10.50	8	45761	511	29906198
Nocturnal dyspnoea	11.24	10.50	8	45761	514	29906195
Acute on chronic liver failure	11.22	10.50	5	45764	128	29906581
Respiratory failure	11.22	10.50	99	45670	100543	29806166
Depersonalisation/derealisation disorder	11.17	10.50	8	45761	519	29906190
Anxiety	11.11	10.50	86	45683	89785	29816924
Costovertebral angle tenderness	11.10	10.50	3	45766	15	29906694
Aortic dissection	11.03	10.50	16	45753	2426	29904283
Lymphocyte count	11.00	10.50	4	45765	59	29906650
Skull fracture	10.94	10.50	10	45759	919	29905790
Cytomegalovirus infection	10.94	10.50	12	45757	23662	29883047
Fatigue	10.86	10.50	391	45378	320282	29586427
Fluid overload	10.83	10.50	8	45761	19084	29887625
Idiopathic pulmonary fibrosis	10.78	10.50	21	45748	4048	29902661
Septic encephalopathy	10.76	10.50	4	45765	63	29906646
Influenza like illness	10.75	10.50	14	45755	25591	29881118
Sinus rhythm	10.71	10.50	6	45763	253	29906456
Catheter site cellulitis	10.67	10.50	5	45764	144	29906565
Tongue haematoma	10.61	10.50	5	45764	146	29906563
Toxic skin eruption	10.61	10.50	39	45730	10976	29895733
Tetany	10.53	10.50	9	45760	757	29905952
Facial paresis	10.51	10.50	17	45752	2833	29903876

Pharmacologic Action:

Source	Code	Description
ATC	C09CA06	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN Angiotensin II receptor blockers (ARBs), plain
ATC	C09DA06	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs) and diuretics
ATC	C09DB07	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs) and calcium channel blockers
ATC	C09DX06	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS Angiotensin II receptor blockers (ARBs), other combinations
MeSH PA	D047228	Angiotensin II Type 1 Receptor Blockers
MeSH PA	D057911	Angiotensin Receptor Antagonists
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
FDA MoA	N0000000070	Angiotensin 2 Receptor Antagonists
FDA EPC	N0000175561	Angiotensin 2 Receptor Blocker

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Chronic heart failure	indication	48447003
Atrial fibrillation	off-label use	49436004	DOID:0060224
Diabetic renal disease	off-label use	127013003
Diastolic heart failure	off-label use	418304008	DOID:9775
Nondiabetic Proteinuric Nephropathy	off-label use
Anuria	contraindication	2472002	DOID:2983
Hypercholesterolemia	contraindication	13644009
Hyperkalemia	contraindication	14140009
Secondary angle-closure glaucoma	contraindication	21571006
Hypovolemia	contraindication	28560003
Dehydration	contraindication	34095006
Hyperuricemia	contraindication	35885006	DOID:1920
Hypokalemia	contraindication	43339004
Low blood pressure	contraindication	45007003
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Sympathectomy	contraindication	57071006
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Hypochloremic alkalosis	contraindication	70134007
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Oliguria	contraindication	83128009
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Hypomagnesemia	contraindication	190855004
Acute pancreatitis	contraindication	197456007	DOID:2913
Impaired renal function disorder	contraindication	197663003
Disease of liver	contraindication	235856003	DOID:409
Neonatal hyperbilirubinemia	contraindication	281610001
Pregnancy, function	contraindication	289908002
Renal artery stenosis	contraindication	302233006
Surgical procedure	contraindication	387713003
Azotemia	contraindication	445009001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.25	acidic
pKa2	3.2	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Type-1 angiotensin II receptor	GPCR	P30556	AGTR1_HUMAN	ANTAGONIST				UNKNOWN	CHEMBL
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	6.16		CHEMBL
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	5.76		CHEMBL
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	5.52		CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.52		CHEMBL
Thromboxane-A synthase	Enzyme	P24557	THAS_HUMAN		IC50	5.51		CHEMBL
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		Ki	5.49		CHEMBL
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	5.48		CHEMBL
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		IC50	5.23		CHEMBL
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	5.05		CHEMBL
Cruzipain	Enzyme		CYSP_TRYCR		IC50	4.38		CHEMBL
Type-1 angiotensin II receptor	GPCR		AGTR1_BOVIN		IC50	6.96		CHEMBL
Type-1 angiotensin II receptor	GPCR		AGTR1_RABIT		Ki	9.19		CHEMBL

External reference:

ID	Source
4021148	VUID
N0000179517	NUI
D00522	KEGG_DRUG
139481-59-7	SECONDARY_CAS_RN
4021148	VANDF
4021151	VANDF
C0527379	UMLSCUI
C0717550	UMLSCUI
CHEBI:3348	CHEBI
CHEBI:149509	CHEBI
CHEMBL1014	ChEMBL_ID
DB00796	DRUGBANK_ID
C077793	MESH_SUPPLEMENTAL_RECORD_UI
2540	PUBCHEM_CID
8352	IUPHAR_LIGAND_ID
C081643	MESH_SUPPLEMENTAL_RECORD_UI
7239	INN_ID
S8Q36MD2XX	UNII
2541	PUBCHEM_CID
587	IUPHAR_LIGAND_ID
DB13919	DRUGBANK_ID
135481	RXNORM
188909	MMSL
7490	MMSL
d04322	MMSL
007275	NDDF
007276	NDDF
108587008	SNOMEDCT_US
372512008	SNOMEDCT_US
386878000	SNOMEDCT_US

Pharmaceutical products:

None